ARTICLE | Clinical News
AVA-101: Phase IIa data
June 22, 2015 7:00 AM UTC
Top-line data from a Phase IIa trial in 32 wet AMD patients ages >=55 showed that a single sub-retinal injection of AVA-101 plus Lucentis ranibizumab on day 0 and at week 4 met the primary safety end...